Postoperative Constipation and Ileus
After pelvic GU surgery, constipation, opioid-induced constipation (OIC), postoperative ileus and mechanical obstruction require different decisions. Assess oral tolerance, vomiting, pain, distension, flatus or stool, medication exposure and the operation performed. A patient with progressive symptoms should not simply move to the next laxative on a postoperative-day schedule.[1][2]
Bowel Preparation
The EAU strongly recommends against preoperative bowel preparation for radical cystectomy; antimicrobial prophylaxis is a separate decision.[3] For elective colorectal resection, ASCRS 2024 concludes that oral antibiotics with mechanical bowel preparation (MBP) decrease surgical-site infection ; when MBP is omitted or contraindicated, it says oral antibiotics alone can reduce infection .[4] The 2025 ERAS Society colorectal guideline advises against routine MBP alone in colonic surgery , allows it selectively for rectal surgery with diversion, and strongly recommends adding oral antibiotics when MBP is used (high-quality evidence).[22] Agree on the procedure-specific pathway with the colorectal team when resection is concomitant.
| Operation | Practical approach |
|---|---|
| Radical cystectomy with urinary diversion | No routine bowel preparation under the EAU pathway |
| GU operation without bowel entry | Do not import a colorectal preparation protocol solely because the operation is pelvic |
| Concomitant elective colorectal resection | Agree the colorectal preparation and systemic antibiotic plan with the colorectal team |
| Unusual colon-based reconstruction or complex fistula repair | Define the bowel procedure explicitly and individualize |
In a propensity-matched NSQIP analysis of 2,054 radical cystectomies (2019–2020; 71% without bowel preparation), oral antibiotic preparation was associated with longer stay after ileal conduit, whereas bowel regimens were associated with shorter stay and no worse outcomes after neobladder.[5] See Bowel preparation for agents and safety.
Prevention and Recovery
Use an operation-specific enhanced-recovery pathway: opioid-sparing analgesia, appropriate hydration, correction of electrolyte abnormalities, early supported mobilization and early oral intake when clinically appropriate. Adapt analgesic choices to renal function, sedation risk and the reconstruction. No single drug combination is suitable for every patient.[6]
For uncomplicated elective colorectal surgery, ASCRS/SAGES recommends offering a regular diet within 24 hours and avoiding routine nasogastric decompression.[6] These principles support early feeding after suitable GU bowel procedures, but established vomiting, obstruction or another complication requires reassessment. After colorectal surgery, chewing gum is an optional adjunct for small GI recovery gains , with inconsistent additional benefit within established recovery pathways; the 2025 ERAS Society guideline says it can be used in multimodal ileus prevention (moderate-quality evidence).[6][22]
When ongoing opioids are needed and bowel function permits laxatives, a stimulant and/or osmotic regimen can be started and titrated to the patient's baseline and response. Docusate alone is not a reliable prevention or treatment strategy. The supporting inpatient consensus primarily concerns medical patients; fresh bowel or rectal repairs need an individualized surgical plan.[7]
Laxative Regimens After Pelvic Reconstructive Surgery
Pelvic reconstructive patients (prolapse, sling, fistula, urethroplasty and similar operations) are usually on opioids for a short time, and straining is undesirable after a fresh repair. A systematic review of urogynecologic surgery found only four randomized trials (344 patients, moderate-quality evidence): laxatives reduced constipation compared with placebo, multiple-agent regimens reduced bothersome constipation more than docusate alone, and preoperative fiber did not help.[14] Trials were small and measured time to first bowel movement, so agent choice and timing are still set locally.
| Agent | Role | Practical point |
|---|---|---|
| Polyethylene glycol (PEG) | Osmotic; strongly recommended by AGA-ACG for adults with chronic idiopathic constipation[15] | Usual dose 17 g once daily in fluid; titrate to soft stool |
| Senna, bisacodyl | Stimulant; targets the reduced propulsion of opioid exposure (senna: conditional AGA-ACG recommendation)[7][15] | Schedule while opioids continue when bowel function permits; titrate to bowel movements and symptoms |
| Docusate | Stool softener | Limited and conflicting evidence; do not rely on it alone[7][14] |
| Suppository or enema | Rescue | Assess for distal impaction and exclude obstruction. An enema may be considered for rectal impaction, but rectal therapy after a fresh rectal or vaginal-rectal repair requires the operating surgeon's agreement.[21] |
Reduce opioid exposure when clinically feasible, select a bowel regimen suited to the operation and baseline bowel function, and track bowel movements daily so the regimen can be adjusted.
Alvimopan: plan before the operation
The US indication is acceleration of gastrointestinal recovery after surgery involving partial bowel resection with primary anastomosis. The labeled course is 12 mg 30 minutes to five hours before surgery, then 12 mg twice daily from the next day until discharge, for no more than seven days or 15 doses in an enrolled hospital. The REMS reflects a boxed warning about a myocardial-infarction imbalance during 12-month treatment for chronic pain; the imbalance was not observed in short-term surgical trials.[8] It is contraindicated after therapeutic opioid use for more than seven consecutive days immediately before treatment. It is not a general rescue prescription for established postoperative ileus or chronic OIC.[8]
In the cystectomy trial, 280 patients were randomized and 277 entered the modified intention-to-treat analysis. Alvimopan shortened the composite time to solid-food tolerance plus bowel movement (5.5 versus 6.8 days) and length of stay (7.4 versus 10.1 days), and reduced ileus-related morbidity (8.4% versus 29.1%).[9] The study largely involved open surgery and postoperative intravenous opioid analgesia. The Cochrane review was based on this same single trial. Incremental benefit may differ with contemporary minimally invasive pathways.[9][10] The AUA/ASCO/SUO guideline recommends a peripherally acting μ-opioid antagonist for patients undergoing radical cystectomy unless contraindicated .[20] Alvimopan starts before surgery and is contraindicated after therapeutic opioid use for more than seven consecutive days immediately before treatment.[20][8]
Opioid-Induced Constipation
Opioids act on mu receptors in the enteric nervous system and gut smooth muscle. They inhibit propulsive motility, increase nonpropulsive segmentation, reduce fluid secretion and raise anal sphincter tone, giving hard stool and difficult evacuation. Tolerance to these gut effects is incomplete, so OIC tends to persist for as long as opioids continue.
OIC is new or worsening constipation associated with opioid exposure, including hard stool, straining and incomplete evacuation, not just infrequent bowel movements. Review other causes and the continuing opioid requirement.[1] The AGA guideline mainly concerns patients with a prolonged opioid requirement.[1]
| Situation | AGA recommendation |
|---|---|
| Confirmed OIC | Traditional laxatives first ; optimize scheduled therapy before calling it refractory[1] |
| Laxative-refractory OIC | Naldemedine or naloxegol (strong; moderate-quality evidence); methylnaltrexone conditionally suggested (low-quality evidence)[1] |
| Lubiprostone or prucalopride for OIC | No recommendation because of evidence gaps |
| Agent (route) | Labeled dose | Label indication |
|---|---|---|
| Naldemedine (oral)[17] | 0.2 mg once daily | OIC, chronic non-cancer pain |
| Naloxegol (oral)[16] | 25 mg once daily on an empty stomach; start at 12.5 mg if CrCl <60 mL/min, or reduce to 12.5 mg if not tolerated. Avoid moderate CYP3A4 inhibitors; if unavoidable, use 12.5 mg and monitor. Strong CYP3A4 inhibitors are contraindicated. | OIC, chronic non-cancer pain |
| Methylnaltrexone (oral or SC)[11] | Chronic non-cancer pain: 450 mg orally or 12 mg SC once daily; if CrCl <60 mL/min, 150 mg orally or 6 mg SC daily; if Child-Pugh B or C, 150 mg orally once daily; in Child-Pugh C, monitor SC adverse effects and consider the label’s weight-based SC reduction. Advanced illness: SC every other day as needed; <38 kg, 0.15 mg/kg; 38–<62 kg, 8 mg; 62–114 kg, 12 mg; >114 kg, 0.15 mg/kg. Reduce advanced-illness doses by half if CrCl <60 mL/min. | OIC in adults with chronic non-cancer pain; injection only for advanced illness or active-cancer pain requiring opioid escalation for palliative care |
| Lubiprostone (oral)[18] | 24 mcg twice daily with food and water; reduce to 16 mcg twice daily for Child-Pugh B and 8 mcg twice daily for Child-Pugh C. It is a chloride-channel activator, not a PAMORA. | OIC in adults with chronic non-cancer pain; efficacy with methadone has not been established |
All four labels contraindicate known or suspected mechanical obstruction. The three OIC PAMORAs are also contraindicated when recurrent-obstruction risk is increased and carry gastrointestinal-perforation warnings for vulnerable bowel. Updated naloxegol and naldemedine labels report fatal postmarketing cases in at-risk patients, including those with recent or prior gastrointestinal surgery.[11][16][17][18] Alvimopan is covered above.
Choose a prescription agent by the actual indication, interactions, organ function and route. For chronic noncancer OIC, stop maintenance laxatives before starting methylnaltrexone and resume them as needed after three days if the response remains suboptimal.[11] Methylnaltrexone dosing and indications differ between chronic noncancer pain and advanced illness; oral and injected regimens are not interchangeable. Its label contraindicates use with known or suspected obstruction or increased recurrent-obstruction risk, warns about perforation in vulnerable bowel, and recognizes possible opioid withdrawal or reduced analgesia. Fresh postoperative distension should be evaluated before prescribing a PAMORA.[11]
Ileus Versus Mechanical Obstruction
Vather and colleagues proposed research endpoints in which POI spans surgery to passage of flatus or stool plus tolerance of an oral diet.[19] Their prolonged-POI endpoint requires at least two of nausea or vomiting, inability to tolerate diet for >24 hours, absence of flatus for >24 hours, distension, or radiologic confirmation, on or after postoperative day 4 without prior resolution.[19] It is impaired propulsion without a mechanical blockage. Recovery varies with the procedure and patient; a fixed “normal through day three” or “image on day five” rule is unsafe. Mechanical obstruction can occur early, including before an apparent return of bowel function. Passing stool or diarrhea does not exclude incomplete obstruction.[2][12]
| Finding | Interpretation |
|---|---|
| Mild constipation with food tolerance and no progressive symptoms | Review medications, hydration and baseline bowel pattern; titrate a suitable laxative regimen |
| Persistent vomiting, increasing distension, focal or severe pain, systemic deterioration | Evaluate promptly for obstruction, leak, infection or another complication |
| Bowel sounds, plain radiograph, passage of a little stool | None reliably excludes a clinically important obstruction |
| CT | Can identify a transition point, hernia, closed loop or another cause; integrate with serial clinical assessment |
For suspected acute SBO, CT abdomen and pelvis with IV contrast is generally preferred when feasible. Oral contrast is not routinely needed for suspected high-grade obstruction and may delay assessment or increase vomiting or aspiration risk. For selected uncomplicated adhesive SBO, failure of water-soluble contrast to reach the colon within 24 hours predicts failure of nonoperative management; the contrast challenge does not replace urgent diagnostic CT.[2][13] A 2025 review of 11 randomized trials did not establish a therapeutic reduction in operations (OR 0.63; 95% CI 0.39–1.01).[23]
Closed-loop obstruction can be mistaken for ileus. Disproportionate pain, focal tenderness, leukocytosis, acidosis, rising lactate, mesenteric edema, reduced wall enhancement or pneumatosis on CT should prompt urgent surgical assessment.[2]
Management and Escalation
- Suspected ileus: reassess the cause, minimize contributing drugs, correct fluid and electrolyte problems and adjust intake to tolerance. Use nasogastric decompression for clinically significant vomiting or distension when needed, rather than routinely. Persistent or worsening symptoms need renewed investigation.[2][6]
- Mechanical obstruction: obtain early surgical review, resuscitate, withhold oral intake and decompress as appropriate. Some adhesive obstructions resolve without surgery. Peritonitis, strangulation, ischemia or a concerning closed loop require urgent operative assessment.[2]
- Timing: Bologna guidance supports a monitored trial of up to about 72 hours for uncomplicated adhesive SBO, with earlier escalation for deterioration. Early postoperative SBO is a distinct setting: there is no agreed universal waiting interval. Do not turn historical 10–14-day observation into a default, especially for an incarcerated port-site or internal hernia.[2][12]
Agree rectal examination, suppositories, enemas or manual disimpaction with the operating team when these could disrupt a recent repair. An absent bowel movement alone is not an indication for a routine postoperative-day-three phosphate enema. Select rescue therapy after assessing the cause, hydration, renal function and the anatomy repaired.
Pharmacology Hub Companions
| Topic | Reference |
|---|---|
| Bowel-preparation agents, oral antibiotics and phosphate-related risks | Bowel preparation |
| Alvimopan labeling, laxatives and the separate acute-colonic-pseudo-obstruction pathway | Post-op bowel & ileus management |
| Multimodal recovery pathway | ERAS |
References
1. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156:218–226. doi:10.1053/j.gastro.2018.07.016
2. ten Broek RPG, Krielen P, Di Saverio S, et al. Bologna guidelines for diagnosis and management of adhesive small bowel obstruction (ASBO): 2017 update. World J Emerg Surg. 2018;13:24. doi:10.1186/s13017-018-0185-2
3. European Association of Urology. Muscle-invasive and Metastatic Bladder Cancer guideline. Disease management: radical cystectomy and perioperative care. 2026. Official guideline.
4. Shogan BD, Vogel JD, Davis BR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Preventing Surgical Site Infection. Dis Colon Rectum. 2024;67:1368–1382. doi:10.1097/DCR.0000000000003450
5. Simhal RK, McPartland C, Wang KR, et al. Bowel regimens before radical cystectomy: An analysis of a modern cohort. Int J Urol. 2025;32:402–408. doi:10.1111/iju.15668
6. Irani JL, Hedrick TL, Miller TE, et al. Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From ASCRS and SAGES. Dis Colon Rectum. 2023;66:15–40. doi:10.1097/DCR.0000000000002650
7. Herzig SJ, Mosher HJ, Calcaterra SL, et al. Improving the Safety of Opioid Use for Acute Non-Cancer Pain in Hospitalized Adults: A Consensus Statement from the Society of Hospital Medicine. J Hosp Med. 2018;13:263–271. doi:10.12788/jhm.2980
8. Alvimopan. US prescribing information. DailyMed.
9. Lee CT, Chang SS, Kamat AM, et al. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014;66:265–272. doi:10.1016/j.eururo.2014.02.036
10. Sultan S, Coles B, Dahm P. Alvimopan for recovery of bowel function after radical cystectomy. Cochrane Database Syst Rev. 2017;5:CD012111. doi:10.1002/14651858.CD012111.pub2
11. RELISTOR (methylnaltrexone bromide). US prescribing information. DailyMed.
12. Ong AW, Myers SR. Early postoperative small bowel obstruction: A review. Am J Surg. 2020;219:535–539. doi:10.1016/j.amjsurg.2019.11.008
13. American College of Radiology. ACR Appropriateness Criteria: Suspected Small-Bowel Obstruction. Official narrative and imaging recommendations.
14. Woodbury CF, Coughlin AC, Dubois B, et al. Prevention of Postoperative Constipation in Urogynecology Patients: A Systematic Review. Urogynecology (Phila). 2023;29(2):175-182. doi:10.1097/SPV.0000000000001281
15. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023;164(7):1086-1106. doi:10.1053/j.gastro.2023.03.214
16. MOVANTIK (naloxegol oxalate). US prescribing information. DailyMed.
17. SYMPROIC (naldemedine). US prescribing information. DailyMed.
18. AMITIZA (lubiprostone). US prescribing information. DailyMed.
19. Vather R, Trivedi S, Bissett I. Defining postoperative ileus: results of a systematic review and global survey. J Gastrointest Surg. 2013;17(5):962-972. doi:10.1007/s11605-013-2148-y
20. Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3-10. doi:10.1097/JU.0000000000003981
21. Cho YS, Lee YJ, Shin JE, et al. "2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation." J Neurogastroenterol Motil. 2023;29(3):271–305. doi:10.5056/jnm23066
22. Gustafsson UO, Rockall TA, Wexner S, et al. "Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations 2025." Surgery. 2025;184:109397. doi:10.1016/j.surg.2025.109397
23. Gowell M, Baker DM, McLachlan G, et al. "Water-soluble contrast agents in adhesional small bowel obstruction: meta-analysis and PRECIS-2 assessment of trials." BJS Open. 2025;9(3):zraf049. doi:10.1093/bjsopen/zraf049